U.S. drug shortages trace back to a decade of Chinese industrial policy, not just thin generic margins

U.S. biopharma dependence on China is the result of a decade of explicit Beijing industrial policy, not just thin U.S. generic margins or concentrated purchasing. A June 2026 Council on Foreign Relations report titled "The Pharma Choke Point" makes that argument on the basis of a yearlong study group of pharmaceutical executives, regulators, China specialists, and former U.S. national security officials.

The Council on Foreign Relations is a major U.S. foreign-policy research organization. Its report traces the structural problem to a specific chain. Beijing subsidized its pharmaceutical and chemical sectors for years, then designated biopharmaceuticals as a strategic sector in its 2015 "Made in China 2025" industrial plan, the same policy package that named semiconductors and artificial intelligence as national priorities. Financing and political mandate backed the buildup through the following decade. As Chinese producers scaled under that support, U.S. buyers optimized for the lowest unit cost. Domestic U.S. capacity became uneconomic. Shortages became structural, and they remain slow to resolve.

Both sides agree on the diagnosis. China dominates the U.S. pharmaceutical supply chain. They disagree on the cause. Pooja Yerramilli conceded in a prior STAT First Opinion essay that China "dominates nearly every step in the pharmaceuticals production process" but argued that U.S. national-security risks from that dependence are overstated. She attributed persistent shortages to thin U.S. generic margins, concentrated purchasing by a small number of large U.S. buyers, and regulatory constraints. The CFR authors respond in the same section. Those factors are real, but they are amplifiers of an upstream geopolitical shift, not the cause. The CFR authors are themselves the authors of the disputed "Pharma Choke Point" report; their position is institutional, not neutral.

The distinction matters because the two diagnoses point to different policy responses. If thin margins and concentrated purchasing are the cause, the U.S. fix is regulatory relief, purchasing reform, or subsidies that close the unit-cost gap. If Chinese state action is the cause, those measures may produce more resilient buyers, but they will not produce more domestic supply. The structural dependence, the share of active pharmaceutical ingredients and key starting materials that sits in China, was built by a foreign industrial strategy, and the U.S. response has to address that directly. The full report recommends expanding U.S. manufacturing incentives, diversifying the supplier base, and stockpiling key starting materials. The test for any of these measures is whether they shrink the upstream geopolitical concentration or only smooth the downstream frictions.

The two explanations are not mutually exclusive. The CFR authors accept that regulatory and purchasing frictions are real. Yerramilli's prior essay conceded China's production dominance but disputed the national-security framing. They disagree on which is the cause and which is the effect. The CFR authors treat thin margins and concentrated purchasing as the consequences of a foreign policy that subsidized a competitor into the U.S. supply chain, not as the original failure.

That framing has implications for what counts as progress. A U.S. resilience package that fixes the regulatory and purchasing side while leaving the upstream concentration untouched will show up in lower drug prices and shorter shortage windows at the buyer level, but the dependence will still sit in the same place. A future U.S.-China disruption to shipments of active pharmaceutical ingredients would expose the gap between buyer-level fixes and supply-level capacity. The structural question is whether the U.S. is willing to pay a recurring premium for domestic capacity that the market will not finance on its own, and whether the answer changes once the cause is named a foreign industrial strategy rather than a domestic market failure.